


Identification of Different Classes of Luminal Progenitor Cells within Prostate Tumors

Graphical Abstract



Authors

Supreet Agarwal, Paul G. Hynes, Heather S. Tillman, ..., Hans C. Clevers, Charles L. Sawyers, Kathleen Kelly

Correspondence

kellyka@mail.nih.gov

In Brief

The characteristics of primary prostate cancer stem/progenitor cells are mostly unknown. Agarwal et al. use an aggressive model of mouse prostate cancer to show two classes of tumor-derived luminal progenitors with distinct differentiation potentials in vitro and in vivo. These findings define prostate cancer cell populations that affect tumor lineage and propagate tumors.

Highlights

- *Pten*/*Tp53*-null prostate tumors are analyzed for progenitor cells and tumor initiation
- Tumors contain self-renewing luminal progenitors not observed in benign prostate
- Autonomous tumor-initiating activity exists in both luminal and basal fractions
- Many luminal progenitors survive in vivo castration



Identification of Different Classes of Luminal Progenitor Cells within Prostate Tumors

Supreet Agarwal,^{1,6} Paul G. Hynes,^{1,6} Heather S. Tillman,¹ Ross Lake,¹ Wassim G. Abou-Kheir,^{1,7} Lei Fang,¹ Orla M. Casey,¹ Amir H. Ameri,¹ Philip L. Martin,² Juan Juan Yin,¹ Phillip J. Iaquinta,³ Wouter R. Karthaus,³ Hans C. Clevers,⁴ Charles L. Sawyers,^{3,5} and Kathleen Kelly^{1,*}

¹Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA

²Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA

³Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

⁴Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences, 3584CT Utrecht, the Netherlands

⁵Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

⁶Co-first author

⁷Present address: Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut 1107-2020, Lebanon

*Correspondence: kellyka@mail.nih.gov

<http://dx.doi.org/10.1016/j.celrep.2015.10.077>

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

SUMMARY

Primary prostate cancer almost always has a luminal phenotype. However, little is known about the stem/progenitor properties of transformed cells within tumors. Using the aggressive Pten/Tp53-null mouse model of prostate cancer, we show that two classes of luminal progenitors exist within a tumor. Not only did tumors contain previously described multipotent progenitors, but also a major population of committed luminal progenitors. Luminal cells, sorted directly from tumors or grown as organoids, initiated tumors of adenocarcinoma or multilineage histological phenotypes, which is consistent with luminal and multipotent differentiation potentials, respectively. Moreover, using organoids we show that the ability of luminal-committed progenitors to self-renew is a tumor-specific property, absent in benign luminal cells. Finally, a significant fraction of luminal progenitors survived *in vivo* castration. In all, these data reveal two luminal tumor populations with different stem/progenitor cell capacities, providing insight into prostate cancer cells that initiate tumors and can influence treatment response.

INTRODUCTION

Epithelial tissues have remarkable capacities to repair damage and maintain homeostasis as a result of cell divisions mediated by stem cells located within special microenvironments (Morrisson and Spradling, 2008). Particularly relevant to tumorigenesis are a variety of recent findings showing that the differentiation pathway of epithelial cells can be plastic. Even committed normal epithelial cells can dedifferentiate to a stem-like state in certain nonhomeostatic conditions of severe injury (summarized

in Blanpain and Fuchs, 2014). This has implications for the “memory” of transformed epithelium relative to re-expression of stem cell lineage properties. An interesting example comes from mammary epithelium. There is evidence for multipotent stem cells in the developing and adult mammary gland (Rios et al., 2014; Van Keymeulen et al., 2011). Following inactivation of BRCA1 in luminal-committed mammary cells, progressive tumors demonstrate reacquisition of multipotent stem cell properties such as combined basal and luminal marker expression (Molyneux et al., 2010). Similarly, for prostate cancer, there are questions about how the cell of origin and/or characteristics of cancer stem/progenitor cell populations may affect various important properties including treatment resistance (Shibata and Shen, 2013; Wang and Shen, 2011; Zong and Goldstein, 2013).

Prostate glands are composed of an outer layer of basal cells expressing KRT5, KRT14, and TP63, an inner layer of secretory, luminal cells expressing KRT8, KRT18, and AR, and rare SYP and CHGA positive neuroendocrine cells (Shen and Abate-Shen, 2010). TP63 is a marker of prostate basal epithelial and stem cells and is required for prostate development (Pignon et al., 2013). Lineage tracing studies based upon cytokeratin drivers have established a number of principles for stem cell hierarchies in the developing and adult prostate (Choi et al., 2012; Ousset et al., 2012; Wang et al., 2013). The majority of regenerative adult stem cells appear to be unipotent (Choi et al., 2012; Wang et al., 2013). In addition, studies using other lineage tracing schemes have described minor populations of multipotent progenitor cells that have not been captured with KRT-specific drivers. Using an inducible NKX3.1-specific CRE driver, a rare (0.7%) population of bipotential luminal cells in the castrate prostate (CARNs) has been described (Wang et al., 2009). In addition, the existence of KRT5^{neg}, KRT14^{neg}, TP63⁺ cells has been observed, as well as the ability of TP63 lineage marked cells to generate luminal epithelial cells in the adult (Lee et al., 2014). Therefore, there are hints of multipotent stem/progenitor cells in the intact (non-castrate) prostate, as well.

Prostate cancer is almost always luminal in phenotype (Humphrey, 2012). Appropriate CRE drivers have been used to analyze the consequences of *Pten* deletion in basal, luminal, and castration-resistant NKX3.1-expressing (CARN) cells. *Pten* deletion in luminal cells and CARNs gave rise to prostatic intra-epithelial neoplasia (PIN)/early cancer and microinvasive adenocarcinoma (Choi et al., 2012; Wang et al., 2009). In addition, *Pten* loss in basal cells led to PIN/early cancer associated with basal to luminal differentiation (Choi et al., 2012; Wang et al., 2013). These studies established that CARNs as well as broadly defined basal and luminal cells can serve as experimental cells of origin for prostate cancer and strongly suggest that *Pten* deletion promotes prostatic epithelial transformation in the context of luminal lineage commitment.

Tumor-initiating cells (TICs), defined by clonal tumor initiation from transplanted cells, have not been analyzed in primary prostate cancers, partly due to the poor transplantation ability of single-cell suspensions of human prostate cancers and low-grade mouse tumors (Toivanen et al., 2011). This may be due to the fragility of fractionated prostate tumor cells, to a high percentage of indolent cells in primary tumors, to a strict requirement for the proper microenvironment, or to other unknown reasons. In Probasin-CRE (PB-CRE) driven *Pten*-null tumors, fractionation and co-transplantation with embryonic urogenital mesenchyme (UGM) of bulk CD49^{hi} basal cells but not CD49^{lo} luminal cells led to the development of histologically abnormal glands, suggesting that transformed cells initiating tumorigenesis exist in the basal cell fraction (Mulholland et al., 2009). However, to date, definitive evidence for clonal tumor-initiating stem cells in primary prostate cancer is lacking (Wang and Shen, 2011).

Prior ex vivo prostate stem/progenitor studies have been constrained by culture conditions that promote basal but not luminal stem/progenitor cell growth (Xin et al., 2007). The recent development of organoid culture methods that support long-term propagation of luminal epithelium has extended our ability to phenotype and manipulate prostate stem/progenitor cells (Chua et al., 2014; Karthaus et al., 2014). Organoid cultures have revealed the presence of multipotent stem/progenitor cells, capable of reconstituting prostate glands in vivo following UGM recombination assays, within the luminal fraction of mouse and human prostates (Chua et al., 2014; Karthaus et al., 2014). In addition, populations of genetically modified, mouse multilineage organoids gave rise to histologically abnormal, hyperproliferative glands in recombination assays, suggesting an ability to serve as cells of origin for prostate cancer (Chua et al., 2014; Karthaus et al., 2014). There have been technical limitations to growing primary human prostate cancer in organoid cultures (Karthaus et al., 2014), and, therefore, the expression of the multilineage stem/progenitor phenotype in primary human prostate cancer has yet to be determined.

Organoid cultures demonstrate a luminal stem/progenitor cell with multilineage potential, although the existence of such stem/progenitor cells has not been observed in adult mouse tissues with luminal KRT driver-dependent tracing schemes, suggesting important questions. First, is multipotentiality conditionally induced in culture or do organoid-defined multipotent luminal cells reflect their in vivo differentiation pathway? Second, is there a definable relationship between multipotent and TP63^{neg}

luminal cells, the latter of which are characteristic of prostate cancer?

Here, we use the aggressive *Pten/Tp53*-null model of mouse prostate cancer in combination with organoid cultures and clonal TIC assays to characterize luminal stem/progenitor cell populations and their relationship to tumorigenesis. *PTEN* and *TP53* are two of the most frequently deleted or mutated genes in primary prostate cancers, which often are co-selected (Boutros et al., 2015; Taylor et al., 2010). In addition, *TP53* is the most selectively enriched altered gene in metastatic castration-resistant prostate cancer (Robinson et al., 2015), and therefore, insights into the functional consequences of *Tp53* inactivation in prostate epithelium will inform the development of hypotheses related to mechanism of metastasis and acquired resistance. Compared to *Pten*-null prostate cancer, the *Pten/Tp53*-null prostate cancer model produces significantly faster growing tumors and early mortality (Chen et al., 2005; Martin et al., 2011). Also, *Pten/Tp53* tumors are more heterogeneous, being composed primarily of adenocarcinoma but also displaying adenosquamous as well as sarcomatoid differentiation at late stages of disease (Martin et al., 2011), suggesting that the PB-CRE4 driver is active in stem cells and/or that *Tp53* deletion leads to a high level of differentiation plasticity. Here, we present evidence delineating stem/progenitor phenotypes and their relationship to pathogenesis. We demonstrate the amplification of transformed, luminal stem/progenitor cells in aggressive primary prostate tumors, show that luminal multipotent and luminal-committed progenitors are serial stages in lineage differentiation, and identify the autonomous tumor-initiating cells in primary prostate tumors.

RESULTS

CD49f and Prominin-1 Fractionate EpCAM⁺ *Pten*^{-/-}, *Tp53*^{-/-} Prostate Adenocarcinoma Cells into Basal and Luminal Populations

To interrogate discreet tumor subpopulations, we analyzed by flow cytometry the expression of various epithelial lineage and/or potential cancer stem cell markers in PB-CRE4, *Pten*^{fl/fl} *Tp53*^{fl/fl} prostate tumors. After excluding hematopoietic and endothelial cells, flow cytometry was used to characterize combinations of markers on EpCAM⁺ tumor cell suspensions. Unlike normal prostate tissue, tumor epithelial populations were not fractionated into subpopulations by either Sca-1 or CD24 surface expression, both of which showed a continuum of relatively strong expression (Figure S1). To separate basal and luminal cells, respectively, EpCAM⁺ cells were separated into CD49^{hi} and CD49^{med/lo} fractions, detecting high and low ITGA6 levels (Figure 1A; Figure S2A). Prominin-1 (PROM1), which is widely expressed on mouse luminal cells (Missol-Kolka et al., 2011), was used to further resolve cell subpopulations. The antibody used here is directed against a protein epitope and not against the controversial stem cell glycosylation epitope, AC133. More than half of the CD49^{med/lo} cells labeled with PROM1 antibody (hereafter referred to as PROM1⁺), whereas there was no appreciable labeling of the CD49^{hi} basal population. Fluorescence-activated cell sorting (FACS) was used to separate and recover three populations from the prostate tissue: CD49^{hi}, PROM1⁺,




Figure 1. CD49f and PROM1 Fractionate EpCAM⁺ *Pten*^{-/-}, *Tp53*^{-/-} Prostate Basal and Luminal Progenitor Populations

(A) Representative FACS plot of CD49f and PROM1 staining of primary EpCAM⁺ *Pten*^{-/-}, *Tp53*^{-/-} prostate cells. P7 (purple), CD49f^{hi}; P8 (orange), PROM1⁺; P9 (green), CD49f^{lo} PROM1^{neg}. (B) qRT-PCR analysis of *Itga6* and *Prom1* gene expression from the indicated cell fractions. RNA levels were normalized to *Gapdh*.

(C and D) qRT-PCR analysis of lineage marker genes in the indicated cell fractions of *Pten*^{-/-}, *Tp53*^{-/-} (C) and WT (D) prostates. The data are reported as mean ± SEM.

(E and F) Quantification by immunofluorescent staining of TP63⁺ KRT5⁺, KRT8⁺, and KRT8⁺/KRT5⁺ cells in the indicated fractions isolated from primary *Pten*^{-/-}, *Tp53*^{-/-} (E) and WT (F) prostate tissue. The average of three independent experiments is shown. The data are reported as mean ± SEM.

(G) Schematic showing that cells from *Pten*^{-/-}, *Tp53*^{-/-} prostates were fractionated and assayed for organoid formation or were transplanted directly into NOD/SCID mice for tumor initiation assays. G1 organoids were harvested, dissociated, and transplanted in vivo to assess tumorigenesis.

See also Figures S1 and S2.

basal cell marker, TP63, indicates a distinct separation of basal and luminal cells.

Interestingly, an analysis of cytokeratin expression suggests different proportions of lineage subpopulations in tumor as compared to WT for both basal and luminal fractions. For the CD49f^{hi} fraction, tumor cells expressed high levels of RNA encoding *Krt5* as well as lower levels of *Krt18*. Immunofluorescent co-staining of KRT5 and KRT8 in the tumor basal fraction demonstrated about 90% KRT5⁺8^{neg}

and CD49f^{lo} PROM1^{neg} cells. The fractions corresponding to CD49f^{hi} and PROM1⁺ each include 5%–20% of the EpCAM⁺ fraction. Post-sort purity scans were performed on all three populations, and purities of >95% were routinely achieved (Figure S2A). Similar FACS distribution profiles were observed for wild-type (i.e., *Pten*^{+/+/}, *Tp53*^{+/+/}, PB-CRE4^{neg} littermates) (Figure S3) and tumor-bearing prostates.

qRT-PCR was used to confirm the differential expression of *Itga6* and *Prom1* in the relevant fractions (Figure 1B) and to interrogate the expression of prostate lineage markers, TP63, KRT5, and KRT18. Importantly, for both tumor and wild-type (WT) prostate, *Tp63* RNA was expressed in the CD49f^{hi} fraction but was almost undetectable in the CD49f^{med/lo} cells (Figures 1C and 1D). Consistent with RNA data, nuclear TP63 immunofluorescence staining demonstrated a significant enrichment (>90%) in the CD49f^{hi} fraction and <3% in CD49f^{med/lo} fractions (Figures 1E and 1F). The distribution of cells expressing the definitive

and a small fraction of KRT5⁺8⁺ cells (Figure 1E). WT CD49f^{hi} cells expressed robust levels of *Krt5* and *Krt18*. Greater than 95% of cells within the basal fraction stained strongly for KRT5, and a significant subpopulation (30%–40%) of cells were composed of KRT5⁺, KRT8⁺, and TP63⁺ co-stained cells (Figure 1F). These data are consistent with publications describing the presence of a substantial population of basal KRT5⁺/KRT8⁺ cells identified by in situ immunofluorescent staining of normal mouse (Peng et al., 2011) and human (van Leenders et al., 2000) prostate tissue as well as in transgenic KRT5 and KRT18 promoter reporter mice (Peng et al., 2011).

KRT staining patterns for the PROM1⁺ fractions from tumor and WT demonstrated approximately 80% KRT8⁺ cells. Tumor-derived cells also frequently expressed low levels of KRT5, suggesting a possible intermediate or transitional phenotype. The CD49f^{lo} PROM1^{neg} fractions contained mostly KRT8⁺ and cytokeratin negative populations.




Figure 2. Tumor-Derived Basal and Luminal Progenitors Are Almost All PTEN Null

(A) Comparison of first-generation organoid formation from wild-type (WT), *Pten*^{-/-}, and *Pten*^{-/-}, *TP53*^{-/-} CD49^{hi} and PROM1⁺ cells. Data are reported as mean % OFUs ± SEM.

(B) Immunohistochemistry (IHC) images of WT and *Pten*^{-/-}, *TP53*^{-/-} CD49^{hi} and PROM1⁺ organoids stained for PTEN and quantification of PTEN⁺ organoids in each fraction. Data are reported as % PTEN⁺ organoids ± SEM. Scale bars represent 100 μm.

(C) IHC images of pS6^{240/242} expression in WT and *Pten*^{-/-}, *TP53*^{-/-} PROM1⁺ organoids. Scale bars represent 50 μm.

(D) Representative IF (KRT5 and AR) and (KRT8 and TP63) images of G1 WT and *Pten*^{-/-}, *TP53*^{-/-} CD49^{hi} organoids.

*Multilineage organoid. Scale bars represent 50 μm. See also Figures S3 and S4.

tively rare luminal fraction progenitors in normal mice (Chua et al., 2014; Karthaus et al., 2014). The organoid forming units (OFUs) for the basal fraction of tumor-bearing prostates was between 20%–40%, demonstrating that the culture conditions used here are highly efficient in promoting clonal basal cell growth. The CD49^{lo} PROM1^{neg} fraction rarely formed organoids and was not further analyzed. Notably, in comparing tumor and WT luminal fractions, organoid formation by the *Pten*^{-/-} *TP53*^{-/-} fraction was about 10-fold greater than wild-type, while the *Pten*^{-/-} tumors demonstrated relatively modest expansion of luminal OFUs.

To determine the relative abundance of WT (i.e., non-*Pten* deleted) progenitors found in *Pten/TP53*-null tumors, organoids derived from the basal and

Tumor-Derived Organoids Are Observed in Both Basal and Luminal Fractions

To begin evaluating the composition of primary tumors with respect to their stem/progenitor phenotypes as well as clonal tumor-initiating activity, we analyzed such properties in fractionated populations of basal and luminal cells (Figure 1G). Using organoid culturing conditions that allow for in vitro growth of basal and luminal stem/progenitor cells (Karthaus et al., 2014), we compared the relative efficiencies of organoid formation from the prostates of WT mice as well as PB-CRE4; *Pten*^{fl/fl}; *TP53*^{fl/fl} and PB-CRE4; *Pten*^{fl/fl} tumor-bearing mice. Because there is a continuum in morphologies from spherical to more complex structures, we use the term “organoids” to signify clonal stem/progenitor growth of >50 μm, regardless of morphology. WT CD49^{hi} and PROM1⁺ fractions showed approximately 20% and 2% organoid forming efficiency, respectively (Figure 2A), consistent with other recently published reports describing rela-

lational progenitors from tumor-bearing and WT mice were stained for PTEN expression. PTEN was expressed in nearly 100% of organoids from WT prostates (Figure 2B) but was seen in ≤2% of either basal and luminal fraction of tumor-derived organoids. Thus, at 14 weeks of age in PB-CRE4-driven *Pten/TP53*-deleted tumors, at which time the prostate is usually significantly enlarged, the majority of cells that grow in organoid cultures are tumor derived and rarely contaminated with WT organoids. A lack of WT cells within the tumor fractions was validated further by expression of floxed *Pten* exon 5 in WT but not tumor organoids (Figure S3). Further, to analyze pathways downstream of *Pten* deletion, we stained sections of organoids for pS6^{240/242}, a target downstream of RPS6KB1 and mTORC1 activation. Luminal-derived organoids from WT prostates showed weak and patchy staining, while *Pten/TP53* organoids were stained uniformly strongly (Figure 2C).




Figure 3. PROM1⁺ Progenitors Show Heterogeneous Phenotypes in Organoid Culture

(A) Representative phase images of first-generation translucent, acinar, and twined organoids generated from PROM1⁺ cells. Organoid morphologies are observed in wild-type (WT) and *Pten*^{-/-}, *TP53*^{-/-} tumor fractions as indicated. Scale bars represent 50 μ m.

(B) Representative IF (KRT5 and AR) and (KRT8 and TP63) images of G1 WT and *Pten*^{-/-}, *TP53*^{-/-} PROM1⁺ organoids. The arrow indicates a luminal WT organoid. Scale bars represent 50 μ m.

(C) Representative phase, IF (KRT5 and KRT8 or KRT5 and TP63), and IHC (pS6^{240/242}) images of G1 *Pten*^{-/-} PROM1⁺ multi-lobulated structures. Scale bars represent 50 μ m.

See also Figure S4.

model are predominantly a tumor-specific, committed basal phenotype.

Luminal Fraction Tumor-Derived Organoids Demonstrate Luminal-Only and Multilineage Phenotypes

The PROM1⁺ fraction from WT mice produced organoids that were heterogeneous in size and translucent with discernable lumen (Figure 3A). The majority of large organoids contained both KRT8⁺/AR⁺ and KRT5⁺/TP63⁺ cells (Figure 3B), similar to the multilineage organoids described previously, and confirm multilineage organoids in both basal and luminal fractions of WT prostate (Karthauss et al., 2014). In addition, there was

a minor number of small, single-layered organoids (denoted by arrow in Figure 3B) containing luminal cells with limited proliferative and self-renewing capacity, as these were no longer observed upon serial passage (see Figure 4A).

PROM1⁺ *Pten*/*TP53*-null tumor organoids were morphologically heterogeneous and notable for the presence of large, complex twined structures, not usually observed in organoids derived from WT prostates (Figure 3A). Sections from fixed organoids as well as time-lapse microscopy suggested that a continuously enlarging central lumen twisted and folded back upon itself to produce twined single lumen-containing structures (Figure S4; Movie S2). Histological analyses revealed two types of organoids: multilineage and luminal only. The multilineage organoids usually displayed a twined structure, suggesting a hyperproliferative phenotype relative to WT multilineage organoids. Interestingly, large luminal-only organoids were not observed in WT prostates suggesting a tumor-specific characteristic. Tumor-specific luminal-only organoids have not been specifically described previously in mouse models of prostate cancer, although luminal organoids have been derived from clinical metastatic adenocarcinoma prostate cancer biopsies (Gao et al., 2014). Luminal-only organoids predominated in frequency at

The CD49^{hi} fractions from WT and *Pten/TP53*-null tumor-derived prostates were characterized in organoid culture (Figure 2D). Histologically in tumors, basal cells were a minor population occurring as scattered individual cells or within uncommon areas of adenocarcinoma (Martin et al., 2011). Organoids from the CD49^{hi} fractions were TP63⁺ with KRT5⁺ peripheral cells and KRT8⁺ cells near lumen. Time-lapse analyses of organoid development showed actively dividing cells in the outer cortex of the CD49^{hi} tumor organoids (Figure S4; Movie S1). The tumor-derived organoids were composed mostly of tightly packed concentric layers with small lumen, which was an abundant phenotype observed in WT prostate organoids as well. One clear difference between WT and tumor organoids was easily observed AR staining in multiple layers of WT organoids and a lack of AR staining in tumor organoids (Figure 2D). In addition, the WT organoids notably contained an infrequent (<10%) population characterized by two to four cell layers around a large lumen, containing basal, luminal, and AR⁺ cells (denoted by an asterisk in Figure 2D), similar to the phenotype of “multilineage organoids” that have recently been described (Karthauss et al., 2014). Taken together, these data suggest that basal cells in the *Pten/TP53*




Figure 4. Differentiation Potential of Multilineage and Luminal Organoids In Vitro and In Vivo

(A) Representative phase images of G1 organoids isolated from WT and *Pten*^{-/-}, *Tp53*^{-/-} PROM1⁺ cells and IF (KRT5⁺KRT8) confocal images of daughter organoids generated from the cloned organoids. Scale bars represent 100 μ m. Note that there are relative differences in magnification for the panels shown.

(B) Representative H&E, IHC (TP63 and AR), and IF (KRT5 and KRT8) images of regions of adenosquamous (left) and adenocarcinoma (right) in tumors generated from G1 PROM1⁺ organoids. The black arrow indicates nuclear TP63 labeling of cells situated along the basement membrane adjacent to an adenocarcinoma gland. Scale bars represent 50 μ m.

Multilineage and Luminal Progenitors Are Serial Stages in Luminal Commitment

Serial passage of *Pten*/*Tp53*-null PROM1⁺ organoids demonstrated con-

tinued presence of both multilineage and luminal phenotypes. In order to analyze the self-renewal and differentiation properties of the progenitors giving rise to the two organoid phenotypes, individual organoids were clonally isolated from G1 organoid populations, serially passaged as a single-cell suspension and subsequently analyzed histologically at G2 or G4 for organoid phenotype (Figure 4A). Individual, tumor-derived organoids passaged at nearly 100% efficiency and were observed for a minimum of six passages. Two types of differentiation patterns were observed from individual tumor organoids: one pattern showed a mixture of multilineage and luminal phenotyped organoids, and the other pattern showed luminal phenotyped organoids only. The former pattern generally correlated with large, twined organoids and the latter with acinar organoids. No cultures contained only multilineage organoids. These data strongly imply that multipotent tumor progenitors produce multilineage and luminal organoids, while luminal-committed tumor organoids renew themselves and maintain a luminal phenotype.

Luminal Progenitor Phenotypes Are Enriched in *Pten*/*Tp53* Co-deleted Tumors Relative to *Pten*-Null-Only Tumors

Serial passage of *Pten*/*Tp53*-null PROM1⁺ organoids demonstrated continued presence of both multilineage and luminal phenotypes. In order to analyze the self-renewal and differentiation properties of the progenitors giving rise to the two organoid phenotypes, individual organoids were clonally isolated from G1 organoid populations, serially passaged as a single-cell suspension and subsequently analyzed histologically at G2 or G4 for organoid phenotype (Figure 4A). Individual, tumor-derived organoids passaged at nearly 100% efficiency and were observed for a minimum of six passages. Two types of differentiation patterns were observed from individual tumor organoids: one pattern showed a mixture of multilineage and luminal phenotyped organoids, and the other pattern showed luminal phenotyped organoids only. The former pattern generally correlated with large, twined organoids and the latter with acinar organoids. No cultures contained only multilineage organoids. These data strongly imply that multipotent tumor progenitors produce multilineage and luminal organoids, while luminal-committed tumor organoids renew themselves and maintain a luminal phenotype.

Similar analyses carried out with individual WT PROM1⁺ organoids showed that large organoids could be efficiently passaged for at least six generations and gave rise to a combination of multilineage and basal organoid phenotypes (Figure 4A), in contrast to multilineage and luminal phenotypes derived from multilineage tumor organoids. These data suggest that *Pten*/*Tp53* loss in multipotent progenitors may increase luminal and decrease basal commitment or survival of daughter progenitors. In addition, we were unable to serially propagate WT luminal-only organoids, unlike tumor-derived luminal organoids.

Because PB-CRE4;*Pten*^{fl/fl};*Tp53*^{fl/fl} and PB-CRE4;*Pten*^{fl/fl} prostates demonstrated distinct distributions of organoids relative to the basal and luminal fractions (Figure 2A) as well as previously characterized differences in prostate cancer pathogenesis (Chen et al., 2005; Martin et al., 2011; Wang et al., 2006), we performed histological analyses on organoids from age-matched (16–18 weeks) prostates for comparison. As anticipated, the *Pten*-null luminal fraction contained relatively few (<10%) luminal (KRT8⁺/TP63^{neg}) organoids >50 μ m, consistent with total organoid plating efficiency (Figure 2A). *Pten*-null-only prostates contained large, solid lobulated structures present in both luminal and basal fractions, which displayed high pS6^{240/242} staining (Figure 3C). Lobules were organized with KRT5⁺/TP63⁺/AR⁺ cells on the periphery and KRT8⁺ cells near the centers, demonstrating histological and morphological characteristics distinct from *Pten*/*Tp53*-null stem/progenitor cells and consistent with deregulated growth of basal multipotent progenitors. These data imply that the loss of *Tp53* in the context of *Pten* deletion specifically supports survival or amplification of luminal-committed progenitors. Our findings are consistent with the described expansion of basal stem/progenitor cells in PB-CRE4;*Pten*^{fl/fl} prostates (Wang et al., 2006) and with the significantly more rapid development of adenocarcinoma in PB-CRE4;*Pten*^{fl/fl};*Tp53*^{fl/fl} compared to PB-CRE4;*Pten*^{fl/fl} prostates (Chen et al., 2005; Martin et al., 2011).

Similar analyses carried out with individual WT PROM1⁺ organoids showed that large organoids could be efficiently passaged for at least six generations and gave rise to a combination of multilineage and basal organoid phenotypes (Figure 4A), in contrast to multilineage and luminal phenotypes derived from multilineage tumor organoids. These data suggest that *Pten*/*Tp53* loss in multipotent progenitors may increase luminal and decrease basal commitment or survival of daughter progenitors. In addition, we were unable to serially propagate WT luminal-only organoids, unlike tumor-derived luminal organoids.

PROM1⁺ Tumor Organoids Display Luminal and Bipotent Differentiation In Vivo

To investigate the tumorigenicity and resulting histopathology of organoids, we performed subcutaneous injection of single-cell suspensions derived from G1 tumor organoids. WT organoids

Table 1. Tumor-Propagating Cell Frequency in Each Population Was Determined by Limiting Dilution Analysis using L-Calc Software with the Transplanted Cell Numbers Shown

	CD49 ^{hi}	PROM1 ⁺
Tumor histology		
Adenocarcinoma	n = 2	n = 4
Adenosquamous	n = 1	n = 2
No. Cells/Injection	No. Mice with Tumors/No. Mice Transplanted	
100–1,200	0/6	0/4
1,200–10,000	1/8	3/8
10,000–50,000	1/7	0/3
50,000–100,000	1/1	3/8
>100,000	0/0	0/0
	3/22	6/23
Frequency of TPC	1/98,060	1/103,032
	0.4724	

Pooled fractions obtained from two to four tumor-bearing animals were used in each experiment. The number of independent experiments was nine CD49^{hi} and eight PROM1⁺. Summary of histological phenotypes of primary transplant tumors is shown.

did not grow under these conditions. PROM1⁺ G1 tumor organoids produced tumors, which contained multiple foci displaying one of two possible phenotypes, embedded in stroma and disorganized tumor cells. One type of focus consisted of irregular, mostly small, adenocarcinoma glands suggesting initiation from a luminal-committed progenitor (Figure 4B, right panels). These glands were composed of KRT8⁺/KRT5^{neg}/AR⁺ cells with no TP63⁺ cells within or adjacent to the glands. The other type of focus demonstrated a consistent adenosquamous histology indicating bipotent lineage differentiation (Figure 4B, left panels). Adenosquamous transformed foci were composed of variably sized glandular structures lined with a layer of luminal cells that often transitioned into an area of disorganized piling at the edge of the lumen with continuation into an adjacent area of squamous differentiation. This histology clearly forms a continuum in lineage transition (Figure S5) and is pathologically distinct from the pattern anticipated for tumors initiated from two or more lineage-committed cells. In addition, squamous histology alone was never observed, providing evidence that tumorigenic basal-committed stem/progenitor cells are exceedingly rare or absent. TP63 staining was strong in the squamous histology and contained in intermittent basilar located cells adjacent to the luminal glandular regions (denoted by an arrow, Figure 4B). A high proportion of cells within adenocarcinoma and squamous histological phenotypes were nuclear AR⁺. These data show that the foci observed in vivo parallel the lineage composition of multilineage (adenosquamous) and luminal (adenocarcinoma) organoids.

By contrast, tumor-derived, CD49^{hi} organoids from several independent cultures did not produce detectable tumor growth after in vivo transplantation. We hypothesize that the majority of *Pten/TP53*-null CD49^{hi} cells are committed basal cells, consistent with the organoid morphologies shown in Figures 2B and 2D. Such cells proliferate well in organoid culture conditions (Figure 2A), but basal cells have been shown in models of

basal keratin CRE-driven *Pten/TP53* deletion to be relatively resistant to oncogenic growth (Choi et al., 2012).

Luminal and Basal TICs Demonstrate Luminal-Committed and Multilineage Tumor-Initiating Activity

Next, we analyzed the tumor-initiating activity of CD49^{hi} and PROM1⁺ fractions isolated directly from primary tumors. Limiting dilution analysis was performed using subcutaneous injection of cells with Matrigel into NOD/SCID mice in the absence of embryonic urogenital mesenchyme (UGM) in order to evaluate autonomous tumorigenic and lineage differentiation activity without exogenous differentiating signals. Cell numbers used for limiting dilution injections ranged from 100 to 100,000 cells per injection (Table 1). For the PROM1⁺ fraction, tumor formation was relatively uncommon, reflecting an autonomous tumor-initiating cell frequency of ~1/100,000. Importantly, two independent tumor histologies were observed: adenosquamous carcinoma and adenocarcinoma with variable amounts of sarcomatoid carcinoma, consistent with histologies found in primary GEM tumors (Martin et al., 2011). Squamous-only tumors were not observed. Epithelial mesenchymal transition (EMT) trans-differentiation of EpCAM⁺ *Pten/TP53*-null adenocarcinoma to sarcomatoid morphology occurs in *Pten/TP53*-null tumors and has been previously characterized (Liu et al., 2012; Martin et al., 2011).

Adenocarcinoma was KRT8⁺/TP63^{neg}/KRT5^{rare} with glands demonstrating a high frequency of AR⁺ cells (Figure 5, right panels). For the adenosquamous tumors, there was clear continuity between adenocarcinoma and squamous histological phenotypes, showing a common origin (Figure 5, left panels). Both adenocarcinoma and basal components were AR⁺. The glandular component was composed of KRT8⁺/TP63^{neg} cells with intermittent TP63⁺ cells in a basal position, while the squamous tumor cells were strongly KRT5⁺/TP63⁺. These data imply that a multipotent stem cell produced prostatic acini organized with basal and luminal components as well as areas of committed basal cell (squamous) tumors. In addition, we observed in one clonally initiated adenosquamous tumor from the PROM1⁺ fraction that serial passage of the initial tumor gave rise to adenocarcinoma tumors in three recipients, demonstrating that luminal-committed TICs can arise from adenosquamous tumors, consistent with the lineages produced by serially passaged individual, multilineage organoids (summarized in Figure 5B).

Tumor-initiating cell assays were performed with the CD49^{hi} fraction. We observed tumor initiation leading to adenocarcinoma and adenosquamous histological phenotypes at a frequency of ~1/100,000 (Table 1). The existence of cells with tumorigenic potential in the basal fraction is consistent with previous analyses demonstrating tumor initiation by bulk populations of PB-CRE4 *Pten^{fl/fl}* basal cells (Mulholland et al., 2009). The presence of TICs contrasts with the lack of tumorigenicity for organoids derived from the CD49^{hi} fraction. Although various explanations are possible, we favor the interpretation that endogenous CD49^{hi} TICs in this model are relatively rare compared to non-tumorigenic *Pten/TP53*-deleted basal cells, and therefore are not routinely recovered in organoid cultures. This would seem inconsistent with a similar TIC frequency between basal and luminal fractions. However, because the relative




Figure 5. PROM1⁺ Cells Demonstrate Luminal-Committed and Multilineage Tumor-Initiating Activity In Vivo

(A) Representative H&E, IHC (AR), and IF (KRT5 and KRT8 or KRT5 and TP63) staining of regions of adenosquamous (left panels) or adenocarcinoma (right panels) from tumors initiated from *Pten*^{-/-}, *TP53*^{-/-} PROM1⁺ cells. White arrows indicate nuclear TP63 staining in adenosquamous tumors. TP63 staining was not observed in adenocarcinoma. Ad, adenocarcinoma region; Sq, squamous carcinoma. Scale bars represent 50 μ m.

(B) Schematic representation of clonally initiated in vitro progenitor activity and tumor phenotypes originating from luminal and basal fractions of *Pten*^{-/-}*TP53*^{-/-} tumors.

See also Figure S5.

efficiencies of tumor initiation by luminal as compared to basal cells under the conditions used here are not known, direct quantitative comparisons between the two fractions cannot be made.

To summarize (Figure 5B), there are multiple autonomous TICs in primary prostate tumors, included within both the CD49^{hi} basal and the PROM1⁺ luminal fractions that give rise to either adenosquamous or adenocarcinoma. These data, based upon analyses of organoid phenotypes and tumorigenicity as well as clonal TIC phenotypes in vivo, strongly support the existence of transformed multipotent and luminal-committed progenitors resulting from PB-CRE4-initiated deletion of *Pten* and *TP53*. Importantly, the existence of multipotent TICs implies that multilineage organoids reflect endogenous progenitors and are not solely a conditional phenotype induced by ex vivo culture.

A Fraction of PROM1⁺ Stem/Progenitor Cells Are Castration Tolerant

A central question in prostate cancer biology is the cellular origins of castration resistance. To begin addressing this question, we have evaluated the in vivo castration sensitivity or tolerance (survival) of progenitors giving rise to organoids. The histopathol-

ogy of castration in 14- to 16-week-old *Pten/TP53*-null tumors was analyzed between 3 days and 6 weeks. Histologically, androgen deprivation led to attenuation in the size of tumor cells, increased vacuolation of luminal-appearing cells, and a subpopulation of cells with increased cytoplasmic basophilia/anaplasia, especially in the ventral prostate. Apoptosis, assayed by nuclear cleaved CASP3, was increased at day 3 and reached plateau levels by day 12, which were maintained for several weeks (Figure S6A). Nuclear AR localization was used as a measure of AR activity in tissue sections (Figure 6A). Following castration, AR staining mostly was diffuse and cytoplasmic, but, by 7 days post-castration, clusters of cells with weak nuclear AR staining and representing less than 10% of total tumor cells were observed in all prostate lobes. Two weeks was chosen as a short-term castration time point to assay the in situ tolerance of stem/progenitor populations for androgen deprivation. Due to the stochastic potential of this model for sarcomatoid transformation, long time points were not feasible.

FACS analysis of tumors from mice castrated 2 weeks earlier demonstrated CD49^{hi}, PROM1⁺, and CD49^{lo} PROM1^{neg} fractions in approximately similar proportions to intact tumors (Figure S6B). RT-PCR analyses of the fractions obtained from




Figure 6. A Fraction of PROM1⁺ Stem/Progenitor Cells Are Castration Tolerant

(A) IHC images of AR staining of *Pten*^{-/-}, *Tp53*^{-/-} prostate tissue from intact animals or 7 days post-castration. Scale bars represent 50 μ m. (B) Histological comparison of PROM1⁺ organoids generated from intact and castrated *Pten*^{-/-}, *Tp53*^{-/-} prostate. (C) Representative IHC AR staining of PROM1⁺ organoids generated from castrated *Pten*^{-/-}, *Tp53*^{-/-} prostate. Scale bars represent 50 μ m. (D) Representative IHC AR staining in tumors generated from castrate *Pten*^{-/-}, *Tp53*^{-/-} G1 PROM1⁺ organoids. Inset a shows invasive cells; inset b shows nuclear atypia. Scale bars represent 50 μ m. (E) Histological comparison of PROM1⁺ organoids generated from non-castrated *Pten*^{-/-}, *Tp53*^{-/-} prostate following enzalutamide treatment and growth for 7 days.

**p \leq 0.01, *p \leq 0.05. See also Figure S6.

castrate as compared to intact tumors revealed population-specific transcription responses (Figure S6C) such as increased levels of *Tp63*, *Krt5*, and *Krt18* in the basal fraction and increased *Clu* in the luminal fraction. *Clu* expression previously has been described as a luminal progenitor marker in PSA-CRE; *Pten*^{flox/flox} mice (Korsten et al., 2009).

Castrated tumor fractions were characterized for the growth and differentiation potential of surviving progenitors in organoid cultures. The CD49^{hi} fraction showed no significant changes in

OFUs (Figure S6D) and no obvious morphological/lineage changes following castration, consistent with undetectable AR expression in most tumor-derived basal organoids (Figure 2D). Histological analyses of harvested PROM1⁺ fraction organoids demonstrated that both multilineage and luminal organoids were reduced following castration (Figure 6B). Because multipotent progenitors can give rise to luminal progenitors, the inhibition or loss of multipotent progenitors in vivo following castration may be reflected in in vitro numbers of both multilineage and luminal organoids. Interestingly, the PROM1⁺ organoids initiated from castrated tumors contained a high percentage of nuclear AR⁺ cells in the presence of dihydrotestosterone (DHT), showing that castrate-tolerant luminal cells retained the potential for AR signaling (Figure 6C). Consistent with this, transplantation of cell suspensions of PROM1⁺ G1 organoids derived from castrated tumors resulted in tumor foci with glandular morphologies (KRT8⁺/AR⁺/TP63^{rare}) embedded in stroma (Figure 6D). Neoplastic epithelial cells formed both low-grade mPIN lesions as well as invasive adenocarcinoma (inset a). Neoplastic cells had expected features of nuclear atypia including a euchromatin pattern and one to two prominent nucleoli (inset b). Therefore, a fraction of luminal progenitor cells appeared to be castration tolerant, some of which were capable of autonomously producing AR⁺ adenocarcinoma in vivo.

To compare castration to autonomous AR inhibition, we added 10 μ M enzalutamide in the absence of DHT at the time of organoid initiation from the luminal fraction of intact (non-castrated) tumors (Figure 6E). Enzalutamide noticeably slowed but did not prevent the growth of PROM1⁺ organoids. Histological analyses showed a statistically significant decrease in numbers of multilineage organoids and a smaller, statistically insignificant decrease in luminal organoids. Overall, enzalutamide treatment confirms the AR-dependence of organoid initiation by a fraction of *Pten*/*Tp53*-null multilineage progenitors but also revealed the resistance to AR inhibition of a significant population of progenitors in the luminal fraction.

DISCUSSION

This study characterizes primary prostate tumors initiated by loss of the common tumor suppressors, *Pten* and *Tp53*, for stem/progenitor phenotypes as assayed by in vitro organoid cultures and in vivo tumor-initiating activity. It has not been routinely possible to culture luminal stem/progenitor cells, which has prevented ex vivo analysis of these important cells in primary prostate tumors, biasing most studies toward primary basal cells or human prostate cancer cell lines (Wang and Shen, 2011). We have observed two classes of self-renewing luminal progenitors in *Pten*/*Tp53*-null tumors, a minor population giving rise to multilineage organoids (multipotent progenitors) and a major population producing luminal-only organoids (luminal committed progenitors) (Figure 5B). Of particular interest is the observation that multilineage organoids give rise to self-renewing luminal organoids, providing additional insight into progenitor subpopulations, lineage stages leading to luminal commitment, and one route of prostate adenocarcinoma histogenesis. We suggest that combined loss of *Pten* and *Tp53* either in the luminal multipotent progenitor or a precursor has revealed a naturally

transient population, possibly by inhibiting the normal rate of differentiation. This interpretation is consistent with considerable evidence linking *Tp53* to the regulation of differentiation in stem cells (Bonizzi et al., 2012; Cicalese et al., 2009).

To date, luminal multipotent progenitor cells have not been observed in lineage tracing experiments (Choi et al., 2012; Ousset et al., 2012; Wang et al., 2013), except in the case of rare CARN's (Wang et al., 2009), prompting questions about the significance of the multipotent progenitors revealed in organoid cultures. We show the existence of multipotent and luminal-committed TICs isolated directly from tumors, producing either adenosquamous carcinoma or adenocarcinoma, respectively. Importantly, the TIC assays used here measured autonomous differentiation potential in the absence of inductive embryonic urogenital mesenchyme (Neubauer et al., 1983; Taylor et al., 2009). Endogenous adenosquamous prostate carcinoma is observed in a fraction of PB-CRE4; *Pten*^{fl/fl}; *Tp53*^{fl/fl} mice (Martin et al., 2011), supporting the concept that transformed multipotent progenitors exist in vivo and can differentiate to both basal and luminal lineages in tumors in situ. It seems likely that the microenvironment will influence lineage commitment, and we note that organoids and TIC assays are performed in the absence of stromal cells. Therefore, it is possible in these assays that the extent of basal cell commitment by multilineage progenitors may be increased relative to the endogenous microenvironment.

Although engineered models of prostate cancer are often used to analyze the consequences of combined genetic mutations (Shen and Abate-Shen, 2010), the effect upon stem/progenitor populations has not been commonly considered. We show here for PB-CRE4-initiated genetic changes that *Tp53* in combination with *Pten* loss demonstrated significantly different stem/progenitor populations compared to *Pten* loss alone. Specifically, *Tp53* loss leads to the presence of luminal multipotent stem/progenitor cells and a self-renewing luminal population, correlated with accelerated adenocarcinoma development, that is absent in *Pten*-null prostates. In addition, it is possible that *Tp53* loss primes for lineage plasticity, similarly to the phenotypic dedifferentiation of luminal mammary epithelium following *Brca1* loss (Molyneux et al., 2010). Analyses of stem/progenitor populations contribute fundamental knowledge for molecular and pathological comparisons of GEM models and for interpretation of target populations responding to therapeutics, as exemplified for castration/enzalutamide sensitivity in Figure 6.

Due to a lack of biomarkers, the extent of innate stem/progenitor subpopulation heterogeneity in human prostate cancer is not known. However, histological heterogeneity is common in castrate-resistant metastatic prostate cancer (Roudier et al., 2003; Shah et al., 2004), suggesting expression of "stemness" properties through pre-existing or acquired mechanisms. With respect to the multipotent progenitor described here, the existence of prostate adenosquamous carcinoma in humans is exceedingly rare (Giannico et al., 2013; Humphrey, 2012). However, the temporal accumulation of mutations in human prostate cancer or the microenvironment may favor luminal differentiation by multipotent progenitors. It remains to be determined whether a luminal multipotent stem/progenitor cell may be a cell of origin or similar to a cancer stem cell population in human prostate cancer. Another population described here, castration-tolerant luminal

progenitor cells, are candidates as potential cellular targets for the accumulation of acquired resistance mutations in response to androgen deprivation therapies (Goldstein et al., 2010). Similarly, castration-tolerant luminal cells have been observed in primary human prostate cancer xenografts (Toivanen et al., 2013). The ability to isolate and assay-specific stem/progenitor populations from mice is an important resource for future investigations into molecular and proteomic markers that uniquely distinguish various stem/progenitor cell populations, which will enable refined lineage tracing approaches and histopathological analyses of clinical samples.

EXPERIMENTAL PROCEDURES

Isolation, Labeling, and FACS Sorting of Primary Prostate Epithelial Cells

Single-cell suspensions of WT and *Pten*^{-/-}; *Tp53*^{-/-} prostate tissue were prepared as previously described (Abou-Kheir et al., 2010). For labeling reactions, cells were resuspended in PBS (without Mg²⁺ or Ca²⁺) containing 1% heat-inactivated fetal bovine serum (FBS). All antibodies and reagents were purchased from BD Pharmingen unless otherwise stated. Fcγ III/II receptors were blocked using anti-CD16/CD32 antibody for 15 min at 4°C. Cells were stained with CD45-FITC, CD31-FITC, Ter-119-FITC, EpCAM-APC-Cy7 (BioLegend), CD49f-PE, and Prominin-1-APC (Miltenyi Biotec) for 30 min at 4°C. 7-Aminoactinomycin D (Sigma) 100 μg ml⁻¹ was added prior to analysis. Cell sorting was performed on FACS Vantage and FACS Aria cell sorters (Becton Dickinson) using FACSDiva software. The FACS gating strategy for CD49f/PROM1 fractionation is shown in (Figure S2A).

Organoid Culture, Passage, and Clone Isolation

Single-cell suspensions were cultured in organoid culture conditions, consisting of embedding cells within a Matrigel matrix and incubating with modified ENR media as described in Karthaus et al. (2014), except that Matrigel-containing cells was spread in a thin ring around the circumference of a six-well plate instead of as a drop. For passage, organoids were harvested and processed to single cells as described (Abou-Kheir et al., 2010) prior to being replated. For isolation of clonal organoids, 1,000 PROM1⁺ cells were seeded on top of a Matrigel-coated well of a six-well plate. Cells were allowed to attach for 30 min at 37 degrees. Subsequently, cells were covered with 1 ml of media containing 5% Matrigel. After 6–7 days, organoids were individually isolated under the microscope, deposited into a single well of a 96-well plate, visually checked for purity, and then trypsinized (0.05%) and seeded as single cells embedded within Matrigel into a 12-well plate. Organoids were then passaged over several generations at least through G6.

Generation of PB-Cre4, *Pten*^{-/-}, *Tp53*^{-/-} Mice

All animal care was provided in accordance with the procedures outlined by the National Cancer Institute Guideline for the Care and Use of Laboratory Animals. PB-Cre4; *Pten*^{-/-}; *Tp53*^{-/-} mice were generated as previously described (Martin et al., 2011). Male NOD/SCID mice (4–6 weeks old) were obtained from the NCI Frederick-Animal Production Program.

Additional methods are included in the Supplemental Experimental Procedures.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, six figures, two tables, and two movies and can be found with this article online at <http://dx.doi.org/10.1016/j.celrep.2015.10.077>.

AUTHOR CONTRIBUTIONS

P.G.H., S.A., W.G.A.-K., and K.K. designed experiments. P.G.H., S.A., R.L., W.G.A.-K., L.F., O.M.C., A.H.A., and J.J.Y. performed experiments and analyzed data. H.S.T. and P.L.M. performed pathology analyses. P.J.I.,

W.R.K., H.C.C., and C.L.S. provided reagents and analyzed data. P.G.H., S.A., and K.K. wrote the manuscript.

ACKNOWLEDGMENTS

We thank Subhadra Banerjee, Barbara Taylor, and Karen Wolcott at the NCI FACS Core Facility and Dr. Yvona Ward at the Center for Cancer Research, LGCP Microscopy Core Facility.

Received: June 23, 2015

Revised: August 27, 2015

Accepted: October 28, 2015

Published: November 25, 2015

REFERENCES

- Abou-Kheir, W.G., Hynes, P.G., Martin, P.L., Pierce, R., and Kelly, K. (2010). Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten^{-/-}-TP53^{-/-} prostate cancer model. *Stem Cells* 28, 2129–2140.
- Blanpain, C., and Fuchs, E. (2014). Stem cell plasticity. Plasticity of epithelial stem cells in tissue regeneration. *Science* 344, 1242–1248.
- Bonizzi, G., Cicalese, A., Insinga, A., and Pelicci, P.G. (2012). The emerging role of p53 in stem cells. *Trends Mol. Med.* 18, 6–12.
- Boutros, P.C., Fraser, M., Harding, N.J., de Borja, R., Trudel, D., Lalonde, E., Meng, A., Hennings-Yeomans, P.H., McPherson, A., Sabelnykova, V.Y., et al. (2015). Spatial genomic heterogeneity within localized, multifocal prostate cancer. *Nat. Genet.* 47, 736–745.
- Chen, Z., Trotman, L.C., Shaffer, D., Lin, H.K., Dotan, Z.A., Niki, M., Koutcher, J.A., Scher, H.I., Ludwig, J.T., Gerald, W., et al. (2005). Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. *Nature* 436, 725–730.
- Choi, N., Zhang, B., Zhang, L., Ittmann, M., and Xin, L. (2012). Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. *Cancer Cell* 21, 253–265.
- Chua, C.W., Shibata, M., Lei, M., Toivanen, R., Barlow, L.J., Bergren, S.K., Badani, K.K., McKiernan, J.M., Benson, M.C., Hibshoosh, H., and Shen, M.M. (2014). Single luminal epithelial progenitors can generate prostate organoids in culture. *Nat. Cell Biol.* 16, 951–961, 1–4.
- Cicalese, A., Bonizzi, G., Pasi, C.E., Faretta, M., Ronzoni, S., Giuliani, B., Brisken, C., Minucci, S., Di Fiore, P.P., and Pelicci, P.G. (2009). The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. *Cell* 138, 1083–1095.
- Gao, D., Vela, I., Sboner, A., Iaquinta, P.J., Karthaus, W.R., Gopalan, A., Dowling, C., Wanjala, J.N., Undvall, E.A., Arora, V.K., et al. (2014). Organoid cultures derived from patients with advanced prostate cancer. *Cell* 159, 176–187.
- Giannico, G.A., Ross, H.M., Lotan, T., and Epstein, J.I. (2013). Aberrant expression of p63 in adenocarcinoma of the prostate: a radical prostatectomy study. *Am. J. Surg. Pathol.* 37, 1401–1406.
- Goldstein, A.S., Huang, J., Guo, C., Garraway, I.P., and Witte, O.N. (2010). Identification of a cell of origin for human prostate cancer. *Science* 329, 568–571.
- Humphrey, P.A. (2012). Histological variants of prostatic carcinoma and their significance. *Histopathology* 60, 59–74.
- Karthaus, W.R., Iaquinta, P.J., Drost, J., Gracanin, A., van Boxtel, R., Wongvipat, J., Dowling, C.M., Gao, D., Begthel, H., Sachs, N., et al. (2014). Identification of multipotent luminal progenitor cells in human prostate organoid cultures. *Cell* 159, 163–175.
- Korsten, H., Ziel-van der Made, A., Ma, X., van der Kwast, T., and Trapman, J. (2009). Accumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer model. *PLoS ONE* 4, e5662.
- Lee, D.K., Liu, Y., Liao, L., Wang, F., and Xu, J. (2014). The prostate basal cell (BC) heterogeneity and the p63-positive BC differentiation spectrum in mice. *Int. J. Biol. Sci.* 10, 1007–1017.
- Liu, Y.N., Abou-Kheir, W., Yin, J.J., Fang, L., Hynes, P., Casey, O., Hu, D., Wan, Y., Seng, V., Sheppard-Tillman, H., et al. (2012). Critical and reciprocal regulation of KLF4 and SLUG in transforming growth factor β -initiated prostate cancer epithelial-mesenchymal transition. *Mol. Cell. Biol.* 32, 941–953.
- Martin, P., Liu, Y.N., Pierce, R., Abou-Kheir, W., Casey, O., Seng, V., Camacho, D., Simpson, R.M., and Kelly, K. (2011). Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition. *Am. J. Pathol.* 179, 422–435.
- Missol-Kolka, E., Karbanová, J., Janich, P., Haase, M., Fargeas, C.A., Huttner, W.B., and Corbeil, D. (2011). Prominin-1 (CD133) is not restricted to stem cells located in the basal compartment of murine and human prostate. *Prostate* 71, 254–267.
- Molyneux, G., Geyer, F.C., Magnay, F.A., McCarthy, A., Kendrick, H., Natrajan, R., Mackay, A., Grigoriadis, A., Tutt, A., Ashworth, A., et al. (2010). BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. *Cell Stem Cell* 7, 403–417.
- Morrison, S.J., and Spradling, A.C. (2008). Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. *Cell* 132, 598–611.
- Mulholland, D.J., Xin, L., Morim, A., Lawson, D., Witte, O., and Wu, H. (2009). Lin-Sca-1+CD49high stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. *Cancer Res.* 69, 8555–8562.
- Neubauer, B.L., Chung, L.W., McCormick, K.A., Taguchi, O., Thompson, T.C., and Cunha, G.R. (1983). Epithelial-mesenchymal interactions in prostatic development. II. Biochemical observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder. *J. Cell Biol.* 96, 1671–1676.
- Ousset, M., Van Keymeulen, A., Bouvencourt, G., Sharma, N., Achouri, Y., Simons, B.D., and Blanpain, C. (2012). Multipotent and unipotent progenitors contribute to prostate postnatal development. *Nat. Cell Biol.* 14, 1131–1138.
- Peng, W., Bao, Y., and Sawicki, J.A. (2011). Epithelial cell-targeted transgene expression enables isolation of cyan fluorescent protein (CFP)-expressing prostate stem/progenitor cells. *Transgenic Res.* 20, 1073–1086.
- Pignon, J.C., Grisanzio, C., Geng, Y., Song, J., Shivdasani, R.A., and Signoretti, S. (2013). p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia. *Proc. Natl. Acad. Sci. USA* 110, 8105–8110.
- Rios, A.C., Fu, N.Y., Lindeman, G.J., and Visvader, J.E. (2014). In situ identification of bipotent stem cells in the mammary gland. *Nature* 506, 322–327.
- Robinson, D., Van Allen, E.M., Wu, Y.M., Schultz, N., Lonigro, R.J., Mosquera, J.M., Montgomery, B., Taplin, M.E., Pritchard, C.C., Attard, G., et al. (2015). Integrative clinical genomics of advanced prostate cancer. *Cell* 161, 1215–1228.
- Roudier, M.P., True, L.D., Higano, C.S., Vesselle, H., Ellis, W., Lange, P., and Vessella, R.L. (2003). Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. *Hum. Pathol.* 34, 646–653.
- Shah, R.B., Mehra, R., Chinnaiyan, A.M., Shen, R., Ghosh, D., Zhou, M., Macvicar, G.R., Varambally, S., Harwood, J., Bismar, T.A., et al. (2004). Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. *Cancer Res.* 64, 9209–9216.
- Shen, M.M., and Abate-Shen, C. (2010). Molecular genetics of prostate cancer: new prospects for old challenges. *Genes Dev.* 24, 1967–2000.
- Shibata, M., and Shen, M.M. (2013). The roots of cancer: stem cells and the basis for tumor heterogeneity. *BioEssays* 35, 253–260.
- Taylor, R.A., Wang, H., Wilkinson, S.E., Richards, M.G., Britt, K.L., Vaillant, F., Lindeman, G.J., Visvader, J.E., Cunha, G.R., St John, J., and Risbridger, G.P. (2009). Lineage enforcement by inductive mesenchyme on adult epithelial stem cells across developmental germ layers. *Stem Cells* 27, 3032–3042.
- Taylor, B.S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B.S., Arora, V.K., Kaushik, P., Cerami, E., Reva, B., et al. (2010). Integrative genomic profiling of human prostate cancer. *Cancer Cell* 18, 11–22.
- Toivanen, R., Berman, D.M., Wang, H., Pedersen, J., Frydenberg, M., Meeker, A.K., Ellem, S.J., Risbridger, G.P., and Taylor, R.A. (2011). Brief report: a

- bioassay to identify primary human prostate cancer repopulating cells. *Stem Cells* 29, 1310–1314.
- Toivanen, R., Frydenberg, M., Murphy, D., Pedersen, J., Ryan, A., Pook, D., Berman, D.M., Taylor, R.A., and Risbridger, G.P.; Australian Prostate Cancer BioResource (2013). A preclinical xenograft model identifies castration-tolerant cancer-repopulating cells in localized prostate tumors. *Sci. Transl. Med.* 5, 187ra71.
- Van Keymeulen, A., Rocha, A.S., Ousset, M., Beck, B., Bouvencourt, G., Rock, J., Sharma, N., Dekoninck, S., and Blanpain, C. (2011). Distinct stem cells contribute to mammary gland development and maintenance. *Nature* 479, 189–193.
- van Leenders, G., Dijkman, H., Hulsbergen-van de Kaa, C., Ruitter, D., and Schalken, J. (2000). Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy. *Lab. Invest.* 80, 1251–1258.
- Wang, Z.A., and Shen, M.M. (2011). Revisiting the concept of cancer stem cells in prostate cancer. *Oncogene* 30, 1261–1271.
- Wang, S., Garcia, A.J., Wu, M., Lawson, D.A., Witte, O.N., and Wu, H. (2006). Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. *Proc. Natl. Acad. Sci. USA* 103, 1480–1485.
- Wang, X., Kruithof-de Julio, M., Economides, K.D., Walker, D., Yu, H., Halli, M.V., Hu, Y.P., Price, S.M., Abate-Shen, C., and Shen, M.M. (2009). A luminal epithelial stem cell that is a cell of origin for prostate cancer. *Nature* 461, 495–500.
- Wang, Z.A., Mitrofanova, A., Bergren, S.K., Abate-Shen, C., Cardiff, R.D., Califano, A., and Shen, M.M. (2013). Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity. *Nat. Cell Biol.* 15, 274–283.
- Xin, L., Lukacs, R.U., Lawson, D.A., Cheng, D., and Witte, O.N. (2007). Self-renewal and multilineage differentiation in vitro from murine prostate stem cells. *Stem Cells* 25, 2760–2769.
- Zong, Y., and Goldstein, A.S. (2013). Adaptation or selection—mechanisms of castration-resistant prostate cancer. *Nat. Rev. Urol.* 10, 90–98.